Education Students Posters Resources Engage Destination Supporters #BeThe1To

Registration Options

Activity Date: 04/07/2019

Target Audience

This course is designed for pharmacists, nurse practitioners or other health care professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Tardive dyskinesia (TD) is an involuntary athetoid or choreiform movement commonly occurring in the tongue, lower face, and jaw, and/or extremities secondary to the treatment with antipsychotic medication for at least a few months. The underlying mechanism for the development of TD has not been definitively determined, which has led to difficulties in identifying treatment options. In April 2017, the Food and Drug Administration (FDA) approved the first two vesicular monoamine transporter 2 (VMAT2) inhibitor medications for the treatment of TD in adults. Nevertheless, TD remains a challenging medication-induced movement disorder for health care professionals to treat due to the ongoing need to prescribe antipsychotics for patients diagnosed with schizophrenia or other psychotic disorders, bipolar disorder, and treatment-resistant depression. Clinical psychiatric pharmacists are in a position to be able to not only assist in the identification of TD in patients prescribed antipsychotics but to also serve as a resource to other clinical providers in terms of strategies for both prevention and treatment of this movement disorder.

Course Requirements

To receive ACPE credit for the live session at the Annual Meeting, you must:

  • Sign in (or create a FREE account).
  • Register for this course. (sign in first)
  • Attend and participate in the entire session and reflect upon its teachings.
  • Complete the evaluation at the end of the activity. (sign in first)
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (sign in first)

This course will be provided at the CPNP 2019 Annual Meeting, April 7-10, 2019. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at

Faculty Information and Disclosures

Steven Clark Stoner, PharmD, BCPP

View biographical information and disclosures

Learning Objectives

  1. Evaluate for the presence and severity of tardive dyskinesia (TD) based on commonly used rating scales.
  2. Assess the safety and efficacy of pharmacologic treatments for TD.
  3. Develop a treatment plan based on the safety and efficacy of the pharmacologic options to treat TD.

Continuing Education Credit and Disclosures

Activity Date: 04/07/2019
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-19-004-L01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.0 contact hour of application-based continuing education credit from CPNP approved programming.